Product Approvals In Brief: Xalkori Gets Full Approval, H5N1 Flu Vaccine Approved
Executive Summary
Pfizer gains full approval for its lung cancer treatment Xalkori, following accelerated approval in 2011; also updates on ID Biomedical’s adjuvanted H5N1 flu vaccine; a new indication for Bayer/Onyx’s cancer treatment Nexavar; a new formulation for Merck’s antifungal Noxafil; and BTG’s new varicose vein product Varithena.
You may also be interested in...
Amgen Wins Onyx, But Will The Deal Pave The Road To Transformation?
The addition of Onyx’s cancer drugs to Amgen’s portfolio will fill a near-term sales gap for the big biotech and reinforce the company as a major oncology player. But Amgen will need to execute expertly on the merger if it is to transform itself into a high-growth biotech.
Pfizer Loses Fight To Persuade NICE Of Xalkori’s Cost-Effectiveness
Pfizer says that it won’t challenge NICE’s final rejection of Xalkori on cost-effectiveness and survival uncertainty grounds.
Some US FDA Decisions May Have Been Different If Technology Had Been Upgraded, Woodcock Says
Principal Deputy Commissioner Woodcock is overseeing an enterprise-wide technology campaign intended to improve access to agency information and data.